Clementia is innovating treatments for ultra-rare bone disorders and other diseases.
Our name represents everything we do. Clementia is derived from the Latin term for compassion, a concept that inspires us every day.
Our mission is to bring innovative and effective treatment options to people who currently have none.
We are developing palovarotene, an investigational retinoic acid receptor gamma (RARγ) selective agonist, for the treatment of individuals who are affected by fibrodysplasia ossificans progressiva (FOP), multiple osteochondromas (MO) and other diseases.
For FOP, we are preparing for a New Drug Application (NDA) for episodic, flare-up based palovarotene treatment, which we intend to submit to the U.S. Food and Drug Administration (FDA) in the second half of 2019, and subject to approval, a U.S. commercial launch in the first half of 2020. We also completed enrollment in our Phase 3 MOVE Trial in FOP in August 2018 with two interim data read-outs planned in 2019. For MO, we enrolled the first patient in our Phase 2 clinical trial in April 2018 – the first ever clinical trial assessing a potential therapeutic option for patients affected by MO – and we expect an interim data read-out in 2020. These devastating bone disorders are caused by genetic mutations that result in excessive cellular signaling in the bone morphogenetic protein (BMP) pathway – signaling that palovarotene disrupts.
We believe that RARγ selective agonists have potential beyond rare bone disorders. We are also developing a palovarotene eye drop formulation for the treatment of dry eye disease, a condition that when advanced, can lead to pain, ulcers, or scars on the cornea, and loss of vision.